Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% compared to 2.4% with tirzepatide 15 mg Based on results of this 48-week Phase 2b study, Lilly will
